Antimicrobial resistance among GLASS pathogens in Morocco: an epidemiological scoping review

Chakib Nejjari1, Youness El Achhab2,3*, Amina Benaouda4 and Chakib Abdelfattah5

Abstract
Background: Monitoring of antimicrobial resistance (AMR) is of great importance due to the frequency of strains becoming increasingly resistant to antibiotics. This review, using a public health focused approach, which aims to understand and describe the current status of AMR in Morocco in relation to WHO priority pathogens and treatment guidelines.

Methods: PubMed, ScienceDirect and Google Scholar Databases and grey literature are searched published articles on antimicrobial drug resistance data for GLASS priority pathogens isolated from Morocco between January 2011 and December 2021. Articles are screened using strict inclusion/exclusion criteria. AMR data is extracted with medians and IQR of resistance rates.

Results: Forty-nine articles are included in the final analysis. The most reported bacterium is Escherichia coli with median resistance rates of 90.9%, 64.0%, and 56.0%, for amoxicillin, amoxicillin-clavulanic acid, and co-trimoxazole, respectively. Colistin had the lowest median resistance with 0.1%. A median resistance of 63.0% is calculated for amoxicillin-clavulanic acid in Klebsiella pneumonia. Imipenem resistance with a median of 74.5% is reported for Acinetobacter baumannii. AMR data for Streptococcus pneumoniae does not exceed 50.0% as a median.

Conclusions: Whilst resistance rates are high for most of GLASS pathogens, there are deficient data to draw vigorous conclusions about the current status AMR in Morocco. The recently join to the GLASS system surveillance will begin to address this data gap.

Keywords: Antimicrobial resistance, Bacteria, Morocco, Global antimicrobial resistance surveillance system, Scoping review

Background
Antimicrobial resistance (AMR) is increasingly recognized as a global public health issue by leading to a high rate of morbidity and mortality [1, 2]. By 2050, the global mortality will have attributed to AMR that could reach 10 million per year; this will pose a significant threat to the global economy if measures are not taken to curb the problem [3]. The antimicrobials misuse and abuse in veterinary and human medicine have accelerated the growing worldwide phenomenon of AMR [4–6]. Moreover, the use of antimicrobials in the food chain endangers sustainable food production and food security [7].

In October 2015, the World Health Organization (WHO) launched the Global Antimicrobial Resistance Surveillance System (GLASS), as a necessary contribution to the global action plan against AMR. Morocco joined GLASS system by the end of 2018 [8]. Recent
AMR data collected from two million patients over 66 countries show high rates of resistance among antimicrobials frequently used to treat common bacterial infections [9]. The main AMR profiles are described as those identified by WHO as “priority pathogens” for the public health significance. There are eight organisms: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Streptococcus pneumoniae, Salmonella spp., Shigella spp., and Neisseria gonorrhoeae [9] (Additional file 2: Appendix 1). Pathogen-antimicrobial combinations under GLASS surveillance include penicillins, third- and fourth-generation cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, tetracyclines, polymyxins, macrolides, and co-trimoxazole.

It is well known that E. coli and K. pneumoniae are the most common pathogens of urinary tract infections (UTIs), which are one of the most common bacterial infections [10–13]. Uropathogenic E. coli strains have a range of adhesins that allow the bacteria to aggregate and adhere to the cellular surfaces [11, 14]. In addition to UTIs, K. pneumonia causes a variety of infectious diseases, including bacteremia, pneumonia, and liver abscesses. K. pneumoniae multidrug-resistant strains are closely related to the antibiotic resistance genes encoded by plasmid [15, 16]. The extensive use and misuse of carbapenems to treat diseases and infections caused by multidrug-resistant gram-negative bacteria contribute to the evolution of plasmid-mediated carbapenemases [17]. A. baumannii and S. aureus are some of the more common opportunistic pathogens which cause community and nosocomial infections. Unfortunately, the number of multidrug-resistant A. baumannii isolates has increased significantly [18, 19]. Resistance to antibiotics is widespread in S. aureus, which methicillin-resistant S. aureus (MRSA) are the most important clinically [20].

S. pneumoniae is an opportunistic pathogen causes pneumonia, meningitis, sepsis, bacteremia, and otitis media, especially in individuals with underdeveloped, weakened, and/or deteriorating immune systems. S. pneumoniae has developed increased resistance to multiple classes of antibiotics [21, 22]. Salmonella belongs to the family Enterobacteriaceae and causes especially gastroenteritis, bacteremia, and enteric fever [23]. Antimicrobial resistance in Salmonella strains is a serious health problem worldwide. Mechanisms of Salmonella resistance are related especially to genes encoding proteins related to drug transport [24, 25]. Shigella causes especially acute gastrointestinal infections and is increasingly becoming highly drug resistant [26–28]. In the same line, Neisseria gonorrhoeae has developed resistance to every antibiotic currently approved for treatment [29].

In Morocco, recently, the Ministry of Health creates the national coordination unit and the technical committee for the surveillance of AMR. However, earliest studies highlighted the resistance seriousness of microorganisms to antibiotics [30–32]. Hitherto, however, these data have not been combined to provide a perspective at a national level. This review aims to describe the recent published AMR data from Morocco and gives a summary of key AMR patterns in the country by focusing on the organisms identified by WHO-GLASS.

**Methods**

**Sources of information and search strategies**

PubMed, SciencDirect, and the Google Scholar were searched for papers from January 1, 2011 to December 20, 2021. Search strategy in PubMed database was performed on MeSH terms (see Additional file 2: Appendix 2). In addition, we researched related reviews and references for relevant studies. The design of this proposed scoping review methodology was informed by Arksey and O’Malley’s framework [33] and The Joanna Briggs Institute Reviewers’ Guidance [34]. The selection of articles for review is done by three-stage method whereby the title alone was examined, followed by looking at the abstract, and then examining the whole article (Fig. 1).

**Eligibility: inclusion and exclusion criteria**

All original articles written in English or French languages reporting the prevalence of antibiotic resistance in bacteria strains isolated from humans by standard laboratory tests are included.

The inclusion criteria include:

- Reports on AMR in humans from Morocco,
- Information about antibiotic resistance of at least one bacterium,
- The denominator as total isolates clearly described for population-based studies,
- Correspondence and abstracts published with sufficient information on methodology and results.

The exclusion criteria include reports published before 2011, studies only focused on HIV or tuberculosis without AMR information, reviews, and studies without information on total studied isolates.

**Article quality assessment**

The quality of each article is assessed using the modified critical appraisal checklist recommended by the Joanna Briggs Institute [35] (Additional file 2: Appendix 3). Quality assessment of studies was performed by two reviewers independently. Disagreements were resolved by a consensus-based discussion. Nine items are used as quality criteria for assessing the design, details
of sample collection, processing and reporting on AMR methodologies.

Data extraction and analysis
Data extraction is done using a predesigned and pre-tested database, developed for the purpose of this review using Microsoft Excel 2016 spreadsheet (Additional file 2: Appendix 4). Data extracted are name of first author, publication date, sample size, time and location of study, laboratory methodological information (pathogen identification and antimicrobial susceptibility testing methodology) and antibacterial resistance data.

Intermediate susceptibility, where reported, is considered as resistant. Where susceptibility rates are reported, without resistance rates, the resistance rates are calculated as the inverse of the susceptibility rates. Two authors independently collected data.

Results
Data and study characteristics
In total, 14,662 articles are collected from the initial literature search, and from them only 61 are eligible for data abstraction (Fig. 1). However, after full assessment, 12 articles are excluded due to data overlapping or duplication [36–38] and for difficulties to abstract data [39–47]. Finally, 49 papers fulfilling the inclusion criteria are included in the final analysis. Characteristics of included studies are summarized in Table 1.

Of the 49 included studies, 13 reported isolates from children only, while 14 not reported age of patients. The majority of included studies [38] used the disk diffusion method as the antibiotic-susceptibility test. Some studies used agar dilution and broth dilution combined, referred to as MIC testing for the analysis. The most commonly reported organism was *E. coli*, with AMR data reported by 22 papers. In contrast, AMR data is reported by one paper for *Shigella* spp. [48], one paper for *N. gonorrhoea* [49] and two papers for *Salmonella* spp. [48, 50] (Table 1).

Microbial resistance patterns

*Escherichia coli*
The most commonly reported bacterium was *E. coli*. It is reported in 22 studies (Table 1). Median resistances are calculated as 64.0% (n=21, IQR 47.1–71.4), 90.9% (n=13, IQR 78.8–95.3), 34.0% (n=23, IQR 26.3–71.7), 56.0% (n=19, IQR 32.7–70.3), 23.0% (n=23, IQR 15.8–53.7), 3.4% (n=22, IQR 2.1–11.0), 47.8% (n=9, IQR 34.9–72.5), and 15.1% (n=11, IQR 6.6–23.9) for amoxicillin-clavulanic acid, amoxicillin, fluoroquinolones, cotrimoxazole, gentamicin, amikacin, nalidixic acid and cefoxitin, respectively (Fig. 2; Additional file 1: Table S1). For 3GC, median resistances are calculated as 28.7% (n=8, IQR 15.7–49.3), 34.4% (n=14, IQR 13.0–71.9), and 31.8% (n=12, IQR 18.0–84.0) for ceftriaxone, cefotaxime and ceftazidime, respectively. Colistin resistance is reported as 0.1% (n=7, IQR 0.0–11.9). Carbapenem
Table 1  Characterization of included studies

| Study | Study design | Time enrolled | Moroccan location | Isolate source and sample | Susceptibility method used | GLASS Organism(s) included |
|-------|--------------|----------------|-------------------|---------------------------|---------------------------|--------------------------|
| [110] | Prospective  | 2008–2009      | Primary health care in Marrakech | 660 nasopharyngeal samples (children under 2 years) | E-test | S. pneumoniae |
| [62]  | Prospective  | 2008           | Ibn Sina UH, Rabat | Nasal carriage of 54 hemodialyzed patients | DDM | S. aureus |
| [111] | Retrospective| Mar 2006–Jun 2010 | Military Hospital Mohammed V, Rabat | 307 samples corresponding to isolate bacterial strains from burn patients | DDM | K. pneumoniae, E. coli |
| [112] | Survey       | 1998–2008      | Ibn Rochd UH of Casablanca | 955 consecutive non-duplicate isolates recovered at the microbiology laboratory | DDM | S. pneumoniae |
| [113] | Prospective  | Jan 2010–Jan 2010 | Private laboratory and Mohammed V Hospital, Meknes | Urine samples from 480 inpatients and outpatients | DDM | E. coli, Klebsiella sp |
| [114] | Surveillance | Sep 2007–Aug 2008 | Ibn Rochd UH of Casablanca | 185 children aged ≤ 5 years diagnosed with bacterial invasive infection | ADM and DDM | S. Pneumoniae |
| [115] | Prospective  | July 2009–Dec 2010 | UH Mohamed VI of Marrakesh | 376 urine cytobacteriology (hospitalized infants) | DDM | E. coli, K. pneumoniae |
| [63]  | Prospective  | Jan–Jul 2007   | Ibn Rochd UH of Casablanca | 160 isolates from pathological samples of patients (79 cases) and nasal swabs (81) of cases and controls | DDM | S. aureus |
| [116] | Prospective  | Jan 2010–Dec 2011 | Casablanca, El Jadida, Settat, Rabat, Meknes, Fez | 1174 community acquired uropathogenic E. coli isolates | DDM | E. coli |
| [59]  | Prospective  | Jan–Dec 2010   | Ibn Sina University Hospital, Rabat | 47 nonduplicate A. baumannii isolated from in-patients | DDM | A. baumannii |
| [117] | Prospective  | Jan – Sep 2009 | Military Hospital Mohammed V, Rabat | Non-redundant isolates of P. aeruginosa and A. baumannii from various samples | DDM | A. baumannii |
| [118] | Prospective  | 2010           | UH Mohammed VI, Marrakech | 38 cases of peritonitis (peritoneal fluid) | DDM | E. coli, K. pneumoniae, Streptococcus spp. |
| [49]  | Retrospective| Jul–Dec 2009   | Five cities situated in north, central, west and south Morocco | 171 men complaining of urethral discharge | E-Test | N. gonorrhoeae |
| [119] | Retrospective| May 2007–May 2009 | UH Mohammed VI, Marrakech and several health centers | Nasopharyngeal samples taken from healthy children aged 1–24 months (660 children) | DDM | S. pneumoniae |
| [64]  | Cross-sectional | Jan to Jun 2012 | Hemodialysis centers in Fez region | Nasal swab specimens (143 hemodialyzed outpatients and 32 medical staff) | DDM | S. aureus |
| [120] | Retrospective| Mar to Jun 2012 | Clinical laboratories in Tangier-Tetouan region | 111 Enterobacteriaceae isolates were collected with patient information | ADM | Enterobacteriaceae |
| [121] | Prospective  | Jan 2011–Jan 2012 | CHU Ibn Sina Rabat | 50 A. baumannii isolates from patients in intensive care unit | E-Test | A. baumannii |
| [122] | Prospective  | Feb 2012–Mar 2013 | CHU Ibn Sina Rabat | Ear swabs were collected from patients at the pediatric hospital | DDM | E. coli, K. pneumoniae, Streptococcus spp. |
| [65]  | Prospective  | Nov 2008–Feb 2009 | Private hemodialysis centres in Casablanca | Nasal swabs (145 patients and 42 personnel) | DDM | S. aureus |
| [123] | Prospective  | Jun–Aug 2011   | Ibn Rochd UH of Casablanca | 166 isolates recovered from urine (n = 80), pus (n = 34), blood (n = 24), sputum (n = 11) and others (n = 17) | DDM | K. pneumoniae |
| Study | Study design | Time enrolled | Moroccan location | Isolate source and sample | Susceptibility method used | GLASS Organism(s) included |
|-------|--------------|---------------|-------------------|---------------------------|----------------------------|---------------------------|
| [124] | Retrospective | Apr 2012–July 2013 | Military Hospital Mohammed V, Rabat | Isolates from inpatients and outpatients. Urine isolates represented 82% | DDM | E. coli |
| [125] | Prospective | Jan 2012–Dec 2013 | UH Mohamed VI of Marrakesh | 406 enterobacteriaceae strains isolated (urinary samples of hospitalized children) | DDM | E. coli, Klebsiella.sp |
| [126] | Retrospective | Nov 2010–Dec 2012 | Mohammed V Hospital Meknes | 150 patients infected by E. coli from hematology (68.7%), urology (22%) and burn (16%) wards | DDM | E. coli |
| [127] | Retrospective | Jan 2010–Dec 2012 | Avicenne Teaching Hospital, Marrakech | E. coli, Klebsiella.sp strains (urine samples) | BMD | K. pneumoniae |
| [128] | Retrospective | 2010–2012 | Avicenne Teaching Hospital, Marrakech | Uropathogenic E. coli (urine samples from in and outpatients) | BMD | E. coli |
| [129] | Prospective | 2007–2014 | Ibn Rochd University Hospital Casablanca | 655 S. pneumoniae isolates (pediatric and adult patients) | DDM | S. pneumoniae |
| [130] | Retrospective | Jan 2012–Dec 2013 | Abderrahim El Harrouchi children hospital of Casablanca | 34 patients (newborns) | ADM | E. coli, K. pneumoniae |
| [48] | Not Mentioned | Mar 2001–Mar 2012 | Pediatric hospital of Rabat | Children under 5 with acute moderate-to-severe diarrhea | DDM | Salmonella spp., E. coli, Shigella spp. |
| [57] | Retrospective | 2012–2014 | Military Hospital Mohammed V, Rabat | Clinical isolates of Acinetobacter sp (samples from inpatients) | DDM | A. baumannii |
| [52] | Prospective | Dec 2012–Nov 2013 | Military Hospital Mohammed V, Rabat | 46 episodes of bacteremia recorded in 39 patients | DDM | A. baumannii, K. pneumonia |
| [131] | Prospective | Feb–July 2013 | UH Hassan II, Fez | Hospitalized neonates (rectal swab specimens) | DDM | E. coli, K. pneumonia |
| [51] | Prospective | 2012–2015 | Laboratories of medical analysis from North-West of Morocco | 516 clinical isolates. Specimens including urine (485), pus (15), vaginal specimens (10) and other ones with low rate | DDM and BMD | E. coli, Klebsiella spp. |
| [56] | Prospective | 2010–2014 | Ibn Rochd University Hospital Casablanca | 4232 non-duplicate blood cultures | DDM | A. baumannii |
| [50] | Prospective | 2003–2009 | Pasteur Ins., Casablanca | 26 isolates from foodstuffs and humans samples | ADM | Salmonella Infantis |
| [66] | Retrospective | Apr 2007–Dec 2015 | Military Hospital Mohammed V, Rabat | 451 wounds, 126 blood cultures and 50 catheter samples from burn inpatients | DDM | E. coli, K. pneumoniae, Streptococcus spp. |
| [132] | Prospective | Feb 2013–July 2015 | UH Hassan II, Fez | Intestinal carriage (newborns hospitalized in neonatal intensive care unit) | DDM | A. baumannii |
| [60] | Prospective | Apr 2015–Jul 2016 | MHI, Regional hospital of Meknes and UH Center of Casablanca | Specimens including urine, pus, distal bronchial Levy protected, bronchial aspirate, central catheter, blood cultures and others | ADM | A. baumannii |
| [133] | Retrospective | Jan 2013–Dec 2017 | UH Mohamed VI of Marrakesh | 4 769 cytopathological examinations of urine (hospitalized children 0–17 years) | DDM | E. coli |
| Study   | Study design | Time enrolled   | Moroccan location                      | Isolate source and sample                                                                 | Susceptibility method used | GLASS Organism(s) included |
|---------|--------------|----------------|----------------------------------------|------------------------------------------------------------------------------------------|---------------------------|---------------------------|
| [61]    | Prospective  | Jun 2017–Jun 2018 | UH Mohamed VI of Marrakesh             | Nasal carriage of *S. aureus* in 300 children consulting at different pediatric specialties | ADM and DDM               | *S. aureus*               |
| [53]    | Retrospective | Jun 2015–Jun 2016 | Mohammed V Hospital Meknes             | 126 burn patients (86 infected)                                                          | DDM                       | *E. Coli*                 |
| [55]    | Case control  | Mar 2015–Mar 2016 | UH Mohamed VI of Marrakesh             | 479 patients from the clinical and surgical ICU enrolled with a first clinical episode of HAI | DDM                       | *A. baumannii*            |
| [134]   | Survey       | 2015–2018       | UH Ibn Rochd, Casablanca               | 19 *S. pneumoniae* isolates (community patients with respiratory tract infections)       | BMD                       | *S. pneumoniae*           |
| [67]    | Case report   | 2017            | UH Ibn Rochd, Casablanca               | 35-year-old female patient. Swab sample from the surgical wound                          | DDM                       | *S. pneumoniae*           |
| [135]   | Prospective  | Feb 2013–July 2015 | UH Hassan II, Fez           | Intestinal carriage (newborns hospitalized in neonatal intensive care unit)            | DDM                       | *E. coli, K. pneumoniae* |
| [136]   | Retrospective | Jan 2016–Jun 2019 | Cheikh Khalifa International UH, Casablanca | Isolates of ESBL-EC isolated from 670 urine samples                                         | DDM                       | *E. coli*                 |
| [137]   | Prospective  | Jan 2017–Dec 2018 | Medical analysis laboratories in Casablanca city | 2090 urines samples collected throughout Casablanca from the health facilities | DDM                       | *E. coli*                 |
| [58]    | Retrospective | Jun 2016–Dec 2018 | UH Mohammed VI of Oujda               | 863 positive blood cultures in the microbiology laboratory (adults, children and newborns) | Not indicated             | *A. baumannii*            |
| [138]   | Retrospective | Jan 2012–Dec 2018 | Military Hospital Mohammed V, Rabat    | 10,324 isolates of *E. coli*                                                             | DDM                       | *E. coli*                 |
| [54]    | Case control  | Jan–Dec 2018    | UH Mohammed VI of Marrakesh            | 131 non-duplicate carbapenem-resistant Enterobacteriaceae                                | DDM                       | *E. coli, K. pneumoniae* |

UH, University hospital; ADM, agar dilution method; DDM, disk diffusion method; BMD, broth microdilution
Resistance is studied in 21 papers and calculated as 3.0\% (IQR 0.0–11.8).

**Klebsiella pneumonia**

AMR data on *K. pneumonia* is reported in 16 studies (Table 1). Median resistances are calculated as 63.0\% (n = 15, IQR 59.5–80.9), 100.0\% (n = 7), 42.9\% (n = 15, IQR 29.8–73.9), 50.9\% (n = 12, IQR 45.6–80.8), 50.0\% (n = 15, IQR 36.8–86.7), 4.9\% (n = 14, IQR 1.4–25.0), 42.9\% (n = 5, IQR 36.4–48.2) for amoxicillin-clavulanic acid, amoxicillin, fluoroquinolones, co-trimoxazole, gentamicin, amikacin and nalidixic acid respectively (Fig. 3; Additional file 1: Table S2). Carabapenem resistance is reported by 15 papers with a median rate of 12.4\% (IQR

### Table 1: AMR Data for *E. coli*

| Antibiotics | Median(IQR)     |
|-------------|-----------------|
| CFX         | 15.1\%(6.6-23.9)|
| Cs          | 0.1\%(0.0-11.9) |
| NA          | 47.8\%(34.9-72.5)|
| AK          | 3.4\%(2.1-11.0)  |
| GN          | 23.0\%(15.8-53.7)|
| SXT         | 56\%(32.7-70.3)  |
| Fluorq.     | 34.0\%(26.3-71.7)|
| Carb.       | 3.0\%(0.0-11.8)  |
| CAZ         | 31.8\%(18.0-84.0)|
| CRO         | 34.4\%(13-71.9)  |
| CTX         | 30\%(0.0-11.8)   |
| AMX         | 90.9\%(78.8-95.3)|
| AMX-C       | 64.0\%(47.1-71.4)|

**Fig. 2** AMR profile of *E. coli* in the form of median resistance with interquartile range. *AK* Amikacin, *AMX-C* Amoxicillin-clavulanic acid, *AMX* amoxicillin, *CRO* Carbapenems, *CRO* Cefotaxime, *CTX* Cefotaxime, *CAZ* Ceftazidime, *CFX* Cefoxitin, *Cs* Colistin, *Fluorq* Fluoroquinolones, *GN* Gentamicin, *NA* Nalidixic acid, *SXT* Trimethoprim-sulfamethoxazole

### Table 2: AMR Data for *K. pneumonia*

| Antibiotics | Median(IQR)     |
|-------------|-----------------|
| NA          | 42.9\%(36.4-48.2)|
| AK          | 4.9\%(1.4-25.0)  |
| GN          | 50.0\%(36.8-86.7)|
| SXT         | 50.9\%(45.6-80.8)|
| Fluorq.     | 42.9\%(29.8-73.9)|
| Carb.       | 12.4\%(6.7-35.0)|
| Cs          | 17.0\%(8.3-24.0)|
| CAZ         | 61.9\%(42.1-85.9)|
| CTX         | 63.7\%(40.4-86.7)|
| CRO         | 58.6\%(52.5-77.5)|
| AMX         | 100\%           |
| AMX-C       | 63.0\%(59.5-80.9)|

**Fig. 3** AMR profile of *K. pneumonia* in the form of median resistance with interquartile range. *AK* Amikacin, *AMX-C* Amoxicillin-clavulanic acid, *AMX* amoxicillin, *CRO* Carbapenems, *CRO* Cefotaxime, *CTX* Cefotaxime, *CAZ* Ceftazidime, *CFX* Cefoxitin, *Cs* Colistin, *Fluorq* Fluoroquinolones, *GN* Gentamicin, *NA* Nalidixic acid, *SXT* Trimethoprim-sulfamethoxazole
For 3GC, median resistances are calculated as 58.6% (n = 6, IQR 52.5–77.5), 63.7% (n = 9, IQR 40.4–86.7), 61.9% (n = 10, IQR 42.1–85.9) for ceftriaxone, ceftazidime and aztreonam respectively. Colistin resistance is reported as 17.0% (IQR 8.3–24.0) in four studies [51–54].

**Acinetobacter baumannii**

Thirteen papers reported data for *A. baumannii* (Table 1). Except for El Mekes et al. study [55], all papers reported imipenem resistance with a median 74.5% (IQR 65.8–79.7). Three studies reported resistance rates of 90.9%, 64.0% and 65.6% to tetracyclines [56–58]. Higher resistance to ticarcillin and piperacillin is reported in nine studies (92.6%, IQR 89.3–100.0) (Fig. 4; Additional file 1: Table S3). AMR resistance to 3GC, especially represented by ceftazidime, was reported as a median of 85.5% (n = 10, IQR 82.9–92.6). Gentamicin and amikacin resistance was reported with rates of 87.0% (n = 9, IQR 79.8–94.0) and 52.3% (n = 11, IQR 47.5–62.8), respectively. Colistin resistance is reported in eight studies as 0.0%, (IQR 0.0–1.2). Cefepime (4CG) resistance is reported by four studies as 87.6% (IQR 86.2–91.2) [57–60].

**Salmonella spp.**

Two papers report resistance data for *Salmonella* spp. in humans [48, 50]. In the study of Benmessaoud et al. [48], resistance to 3CG, 4CG, imipenem and amikacin is not detected. Resistance to tetracyclines, fluoroquinolones (ciprofloxacin and levofloxacin) and co-trimoxazole is reported as 60.0%, 20.0% and 40.0%, respectively. The results reported by Ed-Dra et al. [50] show that 84.6% (22/26) of the *Salmonella infantis* strains were susceptible to all of the 14 antibiotics tested. Three strains are resistant to tetracycline, two strains had low-level β-lactam resistance and one strain is resistant to streptomycin and sulfonamide.

**Shigella spp.**

One study reports AMR data for *Shigella* spp. among five isolates including six *S. sonnei* [48]. No resistance found to 3CG, fluoroquinolones and imipenem. Resistance higher than 50% is reported to tetracycline (55.5%) and co-trimoxazole (66.7% for all strains and 83.3% for *S. sonnei*).

**Neisseria gonorrhoeae**

One study reports AMR data for *N. gonorrhoeae* among 72 isolates recruited from 171 men [49]. Resistance to ciprofloxacin is identified in 86.8% of *N. gonorrhoeae* strains, 16.2% are resistant to penicillin and 92.6% were resistant to tetracycline. All the isolates are 100% susceptible to ceftriaxone, cefixime and spectinomycin. In this study, evolution of resistance in *N. gonorrhoeae* strains isolated in 2001 and 2009 was reported. The AMR study in 2009 demonstrated an increasing trend of resistance in *N. gonorrhoeae* to tetracycline (from 59.7% in 2001 to

---

**Fig. 4** AMR profile of *A. baumannii* in the form of median resistance with interquartile range. AMX-C Amoxicillin-clavulanic acid, SXT Trimethoprim-sulfamethoxazole
92.6% in 2009) and to ciprofloxacin (from 2.6% in 2001 to 86.7% in 2009).

**Staphylococcus aureus**
Six papers report *S. aureus* among human populations [61–66]. MRSA rates range from 1.6% to 31.1%. Dia-wara et al. [64] report that only one strain per 62 isolates (1.6%) expressed an inhibition around cefoxitin and moxalactam disks, which is confirmed as MRSA. In the study of Ed-dyb et al. [61], 49 strains of *S. aureus* are isolated and the prevalence of MRSA is 4% (2/49) of *S. aureus* isolates. The rate of MRSA in hemodialyzed patients is 2.1% (1/47) in the study of Elazhari et al. [65]. In the study of Frikh et al. [66], *S. aureus* is the second most prevalent isolate with a rate of 14.9%, of which 31.1% are MRSA. The prevalence of MRSA strains is 12.5% (3/24) in the study of Souly et al. [62]. The overall prevalence of MRSA in the study of Zrouil et al. [63] is 18.4%.

**Streptococcus pneumoniae**
AMR data for *St. pneumoniae* is reported by seven studies and does not exceed 50.0% as a median (resistance to tetracycline with IQR 30.5–83.7) (Table 1; Fig. 5; Additional file 1: Table S4). Resistance to penicillin G, cotrimoxazole, erythromycin is reported as 36.7% (n = 6, IQR 10.0–86.1), 33.3% (n = 5, IQR 19.8–46.1) and 21.0% (n = 5, IQR 15.5–81.0), respectively. Ceftriaxone resistance is reported by four studies as a median of 5.8% (IQR 0.3–30.4).

In a case study [67], Néhémie et al. reported characteristics of a 35-year-old female patient. An ovarian transposition is performed in the Ibn Rochd University Hospital Centre of Casablanca. Antibiotic susceptibility tests are performed by disc diffusion and E-test method. The strain isolated is resistant to oxacillin, erythromycin, ampicillin, clindamycin, penicillin G and co-trimoxazole. It is only susceptible to vancomycin, levofloxacin and chloramphenicol and intermediate to ceftriaxone.

**Discussion**
Over the last decade in Morocco, there has been no comprehensive review dealing with the AMR prevalence using the global antimicrobial resistance surveillance system (GLASS). This attempt seeks, hopefully, to fill the gap and clarify the AMR status in the country’s regions. The AMR data depicts high heterogeneity due to unstandardized laboratory methods, clinical conditions, and a few isolates. This makes drawing firm conclusions highly challenging. However, resistance rates to several key clinically important antibiotics are found to be alarmingly high.

To this end, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards are recommended over the Clinical and Laboratory Standards Institute (CLSI) guidelines. Moreover, improved access to quality assurance is needed to enhance the current WHO initiative, and scale up the global antimicrobial surveillance system (GLASS) based on country-specific priority pathogens [9].

In a recent systematic review conducted in the MENA region [68], it is shown that the lack of consistency and harmonization in the regional surveillance system is not a prerogative of the Middle East, as is the case in developed countries.

The most frequently GLASS pathogens belong to the Enterobacteriaceae family (*E. coli* and *K. pneumoniae*), *A. baumannii*, and *S. aureus*. They have been described in most of selected papers. Other systematic reviews, conducted on AMR in the Middle East [68] and Africa [69], have reported the same results. Concerning *Shigella*

| Antibiotics | Median(IQR) |
|-------------|-------------|
| SXT         | 33.3%(19.8-46.1) |
| Chloramphenicol | 8.1%(0.0-38.0) |
| Erythromycin | 21.0%(15.5-81.0) |
| Tetracycline | 50.0%(30.5-83.7) |
| Ceftriaxone  | 5.8%(0.3-30.4) |
| Amoxicillin  | 7.4%(2.7-33.5) |
| Penicillin G | 36.7%(10.0-86.1) |

**Fig. 5** AMR profile of *St. pneumoniae* in the form of median resistance with interquartile range. SXT Trimethoprim-sulfamethoxazole.
spp. and *N. gonorrhoeae*, each has been cited by only one paper. *Shigella* spp. is the second leading cause of diarrhoeal mortality, which accounts for 13.2% of diarrhoeal deaths globally [70] whereas, *N. gonorrhoeae* causes high levels of morbidity in LMICs, and shows the rapid development of AMR [8, 9].

Enterobacterales are a large order of different types of bacteria that commonly cause infections both in healthcare settings and communities. This family represented especially by *E. coli* and *K. pneumoniae* can produce extended-spectrum beta-lactamases (ESBLs) Enzymes. The latter break down some commonly used antibiotics such as penicillins and cephalosporins, which render them inefficient [71]. The WHO has recently published a global priority list of antibiotic-resistant bacteria, which includes ESBL-producing *Enterobacteriaceae* and carbapenemase-producing *Enterobacteriaceae* [8, 9]. Carbapenem belong to the category of β-lactams, which has a broader spectrum of activity. It bind to the bacterial cell wall and inhibits growth. It also results in damage to the cell wall, which frequently leads to cell lysis and death [13, 72, 73]. Carbapenem resistance may be caused by different mechanisms, one of them being inducible over-expression of chromosomal cephalosporinases combined with porin loss [74, 75]. *Enterobacteriaceae* with ESBL/ carbapenemase genes are bestowed with highly multi-drug resistance among humans, animals, and food chains [76]. Moreover, careless use of these antibiotic classes would co-select for resistance genotypes against the others [76].

The proportion of AMR driven from this review is alarming. The highest proportion of studies on both *E. coli* and *K. pneumoniae* are related to UTIs. Such cases require more complex treatments [9]. Such infections might require hospitalization and intravenous injection of carbapenem antibiotics. In this review, the carbapenem-resistance proportion among GLASS *Enterobacteriaceae* appears like other reports from Africa [69] and the Middle East [68], but higher than those described in most European countries [77]. In this context, the prevalence of carbapenemase-producing *K. pneumoniae* and *E. coli*, per 10,000 hospital admissions, presents an average of 1.3 (6.0 in Italy, 0.02 in Norway). The incidence per 100,000 hospital patient-days ranged from 17.3 in Greece to 0.09 in Lithuania, with a mean of 2.5 across all the countries. In China, the overall carbapenem-resistant *Enterobacteriaceae* infection incidence per 10,000 discharges was 4.0 and varies significantly by region [78]. However, no carbapenem-resistant *Enterobacteriaceae* is found in a recent systematic review from Cambodia [79]. Carbapenemases have a global distribution, but substantial variability exists at the regional and continental levels.

Recently, different products are under evaluation and over thirty antibiotics are active against the most dangerous pathogens included in the WHO’s priority pathogens [80, 81]. Many of them consist of combinations of new β-lactams and β-lactam inhibitors. d-mannose derivatives and glycomimetics are reported as a promising, valuable, effective, feasible and cost-effective way to treat UTIs especially, urgent clinical trials [82, 83].

In the past decade, numerous review papers have highlighted the rising problem of colistin resistance worldwide, especially with *E. coli*, *K. pneumonia*, and *A. Baumanii* in the human community [16, 68, 69, 84–87]. Current and emerging colistin resistance may be explained by its high usage in the animal field, and this not only as an infection-healing drug but also as a growth promoter and protective agent [88]. Following this study, several reviews have also reported high 3GC, co-trimoxazole, fluoroquinolones, and gentamicin resistance among *E. coli* and *K. pneumoniae* isolates [68, 69, 87].

In the current review, the pathogens isolated from humans such as *Salmonella* spp., *Shigella* spp., and *N. gonorrhoeae* are understudied in the Morocco context. However, AMR in *Salmonella* spp. from foods and environmental sources is mentioned by several studies [89, 90]. Such finding is also revealed by other systematic reviews in other countries [68, 69]. On the other hand, *N. gonorrhoeae* is known for its high resistance to ciprofloxacin [91, 92]. Of note, ciprofloxacin, which is used to treat gonococcal infections, done by, was replaced by ceftriaxone in the Moroccan context [49]. This decision is sustained by previous studies [93] stating that penicillin, tetracycline, and ciprofloxacin should not be used for *N. gonorrhoeae* management in Morocco. For *Salmonella* spp., the prevalence of fluoroquinolone resistance has exceeded 30% in many areas of the Arab World [94]. This remains significantly high when compared with the Moroccan context, where it does not surpass 20%. As recommended by Ranjbar et al. [28] a clear virulence gene profile of *Shigella* may lead to have an accurate diagnosis and a definite treatment relating to different pathogenic strains. In a recent study on *Shigella* in Morocco, the dual contribution of SfGtr4 and SfPgdA genes to the pathogenicity and the regulation biofilm formation by *S. flexneri* is demonstrated [95].

The epidemiology of *S. aureus*, especially that of MRSA, has shown a rapid evolution over the last years. Global surveillance has emphasized that MRSA represents a problem in all countries showing an increase in the mortality and need to use last-resource antibiotics [8,
The proportion of MRSA (30%) reported in this review is still higher than that mentioned in the European countries (16.9%) [97], but lower than those reported in Asia (28–70%) [98], and Africa (53%) [99]. While the treatment options for MRSA are still limited, there are several new antimicrobials under development [100]. S. pneumoniae is reported as a major cause of community-acquired pneumonia, meningitis, sepsis, bacteremia, and otitis media [101, 102]. A decline in susceptibility of S. pneumoniae to commonly used beta-lactams, fluoroquinolones, and macrolides is mentioned by several studies [101, 103, 104].

Although the findings of this study may seem useful, some limitations must be considered when the interpretation of the results is required. The strict focus on GLASS bacteria might have led to oversight of important pathogens like Helicobacter pylori [105, 106], and Pseudomonas aeruginosa [107, 108], which are of significant public health concern in AMR. The Validity and generalizability of the findings to the entire country’s regions might be affected by the clinical-based, cross-sectional study design of the published papers, mainly collected from Casablanca and Marrakech cities. Besides, there is high variability among the criteria relevant to methodology and interpretation. This is consonant with the data depicted elsewhere in recent similar reviews [68, 69, 79, 87]. There are some calls to adopt standardized AMR data presented in published papers, wishing to make the findings interpretable and comparable from the perspective of scarce homogeneity [109]. Despite these limitations, the high proportion of AMR detected in this review has a certain degree of validity.

Conclusions
In summary, this review highlights that data on AMR in Morocco are limited but improving. Overall, there are significant similarities in AMR tendency in comparison with other countries worldwide. The recent joining of Morocco to the GLASS system will improve the accuracy, quality, and comparability of data collected on AMR.

Abbreviations
AABRI: Acinetobacter baumannii resistant to imipenem; ADM: Agar dilution method; AK: Amikacin; AMR: Antimicrobial resistance; AMX-C: Amoxicillin-clavulanic acid; AMX: Amoxicillin; BMD: Broth microdilution; C3G: Third-generation cephalosporins; Carb: Carbapenems; CAZ: Cefazidime; CFX: Cefoxitin; CIP: Ciprofloxacin; CLSI: Clinical and Laboratory Standards Institute; CRO: Ceftriaxone; Cs: Colistin; CTX: Cefotaxime; DDM: Disk diffusion method; ESBL: Extended spectrum beta lactamase; E Test: Epsilometer test; E. coli: Escherichia coli; EUCAST: European Committee on Antimicrobial Susceptibility Testing; GLASS: Global antimicrobial resistance surveillance system; GM: Gentamicin; Fluorq: Fluoroquinolones; HIV: Human immunodeficiency virus; MENA: Middle East and North Africa; IQR: Interquartile range; MIC: Minimum inhibitory concentration; NA: Nalidixic acid; MRSA: Methicillin-resistant Staphylococcus aureus; SXT: Trimethoprim-sulfamethoxazole; UH: University Hospital; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07412-4.

Acknowledgements
The authors would like to thank language-editing service monitored by Professor Kamal EL AISSAOUI and would also like to thank referees for their valuable comments.

Author contributions
Study concept and design: CN and YE. Acquisition of data: CN and YE. Analysis and interpretation of data: CN, YE, AB and CA. Drafting of the manuscript: CN and YE. Critical revision of the manuscript for important intellectual content: All authors. All the authors read and approved the final version of the manuscript.

Funding
This study is sponsored by Sothema, which included compensation for services related to preparing this manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its Additional files.

Declarations
Ethics approval and consent to participate
Not applicable in virtue of the study design (systematic literature review).

Consent for publication
Not applicable in virtue of the study design (systematic literature review).

Competing interests
The authors declare that they have no competing interests.

Author details
1International School of Public Health, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco. 2Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine and Pharmacy of Fez, University Sidi Mohamed Ben Abdellah, Km 2.2 Rte Sidi Harazem, BP 1893, Fez, Morocco. 3CRMEF Fez-Meknes, Rue Kuwait, BP 49, Fez, Morocco. 4Department of Microbiology, Cheikh Zayed International University Hospital, Rabat, Morocco. 5Department of Infectious Diseases, Faculty of Medicine, University Hassan II, Casablanca, Morocco.

Received: 16 January 2022   Accepted: 19 April 2022

Published online: 07 May 2022

References
1. Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN, Holmes AH, et al. Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infect Dis. 2019;19:e392–8.
2. Ferri M, Ranucci E, Romagnoli P, Gaione V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57:2857–76.

3. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance. 2016.

4. Ferri M, Ranucci E, Romagnoli P, Gaione V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57:2857.

5. Pieri A, Aschbacher R, Fasani G, Mariella J, Brusetti L, Pagani E, et al. Country income is only one of the tiles: the global journey of antimicrobial resistance among humans, animals, and environment. Antibiotics. 2020;9:473.

6. Bourrély C, Coeffe T, Caillon J, Thibaut S, Cazeau G, Jouy E, et al. Trends in antimicrobial resistance among Escherichia coli from defined infections in humans and animals. J Antimicrob Chemother. 2020;75:1525.

7. George A. Antimicrobial resistance (AMR) in the food chain: trade, health and codex. Trop Med Infect Dis. 2019;4:54.

8. WHO. Global antimicrobial resistance surveillance system (GLASS) report. Early implementation 2017–2018. 2018.

9. WHO. Global antimicrobial resistance and surveillance system (GLASS) report. Early implementation 2020. 2020.

10. Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18:211–26.

11. Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. 2021;1523:35–69.

12. Khonsari MS, Behzadi P, Foroohi F. The prevalence of type 3 fimbriae in Uropathogenic Escherichia coli isolated from clinical urine samples. Meta Gene. 2021;28:100881.

13. Issakhanian L, Behzadi P. Antimicrobial agents and urinary tract infections. Curr Pharm Des. 2019;25:1409–23.

14. Hozzari A, Behzadi P, Kerischi Khabani P, Sholeh M, Sabokroo N. Clinical cases, drug resistance, and virulence genes profiling in Uropathogenic Escherichia coli. J Appl Genet. 2020;61:265–73.

15. Effah CY, Sun T, Liu S, Wu Y. Clinical considerations for treating infections caused by multi-drug resistant Acinetobacter baumannii. J Infect. 2020;81:857–61.

16. Cheung QYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2012;15:574–69.

17. Cherazard R, Epstein M, Doan T-L, Salim T, Bharti S, Smith MA. Antimicrobial resistant Strepptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. 2017;24:e361–9.

18. Kim L, Mcgee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Strepptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29:525–52.

19. Eng S-K, Pusparajah P, Ab Mutalib N-S, Ser H-L, Chan K-G, Lee L-H. Salmonella: a review on pathogenesis, epidemiology and antibiotic resistance. Front Life Sci. 2015;8:284–93.

20. Shahseen A, Taris A, Sheshadri A, Jobal M, Mirza O, Maslow DA, et al. Transcriptional regulation of drug resistance mechanisms in Salmonella: a review. Pathogens. 2021;10:801.

21. Moradi F, Hadi N, Akbari M, Hashemizadeh Z, Rouhi Jahromi R. Frequency and antimicrobial resistance of Shigella species in Iran during 2000–2020. Jundishapur J Health Sci. 2021;13.

22. Muthurulandi Sethuvel DP, Devanga Ragupathi NK, Anandan S, Veeraraghavan B. Update on: Shigella new serogroups/serotypes and their antimicrobial resistance. Lett Appl Microbiol. 2017;64:8–18.

23. Ranjarb B, Bolandian M, Behzadi P. Virulotyping of Shigella spp. isolated from pediatric patients in Tehran, Iran. Acta Microbiol Immunol Hung. 2017;64:71–80.

24. Aitolo GL, Adeyemi OS, Afolabi BL, Owolabi AO. Neisseria gonorrhoeae antimicrobial resistance: past to present to future. Curr Microbiol. 2021;78:867–78.

25. Filali E, Bell J, Ethouaöffdi M, Huggins M, Cook J. Antibiotic resistance of Escherichia coli strains isolated from chickens with colisepticemia in Morocco. Comparat Immunol Microbiol Infect Dis. 1988;11.

26. Amable-Cuevas CF. Antimicrobial resistance in developing countries. New York: Springer; New York, 2010.

27. Ousaid A, Akrim J, Khayati Y. Overuse of antibiotics as a key driver to antibiotic resistance in Morocco: a short review with potential solutions. Int Arab J Antimicrob Agents. 2020;10.

28. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.

29. Peters MDJ, Godfrey CM, Khalil H, Mcherney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141.

30. Munn Z, Moola S, Lisy K, Rittano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2013;15:147.

31. Bennessouad R, Jroundi I, Moradella C, Alvarez-Martínez MJ, Pons MJ, Chaacho S, et al. Aetiology, epidemiology and clinical characteristics of acute moderate-to-severe diarrhoea in children under 5 years of age hospitalized in a referral paediatric hospital in Rabat, Morocco. J Med Microbiol. 2015;64:84–92.

32. El Bouamri MC, Arsalane L, Kamouny V, Berraha M, Zouhri S. Évolution récente du profil épidémiologique des entérobactéries uropathogènes productrices de β-lactamases à spectre élargi à Marrakech. Maroc Progr Urol. 2014;24:451–5.

33. El Bouamri MC, Arsalane L, Kamouny V, Yahyaoui H, Bennouar N, Berraha M, et al. Profil actuel de résistance aux antibiotiques des souches d’Escherichia coli uropathogènes et conséquences thérapeutiques. Prog Urol. 2014;24:1058–62.

34. Barguiguia A, el Otmani F, Talmi M, Bourjilt F, Haouzane F, Zoueiri K, et al. Characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco. J Med Microbiol. 2011;60:1344–52.

35. Bourjilt F, Bouchrif B, Dersi N, David J, Gros Claude P, Amorah J, et al. Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary infections in Casablanca, Morocco. J Infect Dev Ctries. 2011;5:850.

36. el Hamzaoui N, Barguiguia A, Nayme K, Mohamed S, Timinouni M, Louzi L. Prevalence of extended-spectrum beta-lactamases in uropathogenic Enterobacteriaceae isolated from a community setting, Meknos, Morocco. Gene Rep. 2020;19:100652.

37. le Hello S, Haroos D, Bouchrif B, Sonntag L, Elharbi D, Guibert V, et al. Highly drug-resistant Salmonella enterica serotype Kentucky ST198-X1: a microbiological study. Lancet Infect Dis. 2013;13:672–9.

38. Natoubi S, Barguiguia A, Diawara I, Timinouni M, Rakib K, Amghar S, et al. Epidemiology of extended-spectrum betalactamases and carbapenemases producing Enterobacteriaceae in Morocco. J Contemp Clin Pract. 2020;21:2040–58.

39. Amel Kebbel, J. Klein, S. Flahault, A. Abraham, P. et al. Évolution des résistances de l’Escherichia coli au cours des périodes communautaires. Méd Maladies Infect. 2011;41:218–20.

40. Ambrose J, Benassa E, Irenge LMWB, Belouad EM, Bearzatto B, Durant J-F, et al. Genomic characterisation of extended-spectrum β-lactamase-producing multidrug-resistant Escherichia coli in Rabat, Morocco. J Glob Antimicrob Resist. 2021;26:335–41.

41. Farih S, Sadadi A, Nousaibah A, Abara A, Yacoubi L, Benissa E, et al. Health vigilance concerning female urinary tract infections: epidemiological profile and antibiotic resistance. E3S Web Conf. 2021;319:01009.
48. Bennessaoud R, Nezha M, Moraleda C, Jroundi I, Tilgui H, Seffar M, et al. Antimicrobial resistance levels among diarrhoeagenic micro-organisms recovered from children under-5 with acute moderate-to-severe diarrhoea in Rabat, Morocco. J Glob Antimicrob Resist. 2016;7:34–6.

49. Hançali A, Nidowa F, Belaij B, Bennara A, Kettani A, Charof R, et al. Antimicrobial resistance monitoring in Neisseria gonorrhoeae and strategic use of funds from the Global Fund to set up a systematic Moroccan gonococcal antimicrobial surveillance programme. Sexually Transm Infect. 2013;89(Suppl 4).

50. Ed-Dra A, Karraouan B, Allouaie A, Khayatt M, Ossmaniel H, Filali FR, et al. Antimicrobial resistance and genetic diversity of Salmonella Infantis isolated from foods and human samples in Morocco. J Glob Antimicrob Resist. 2018;14:297–301.

51. Benacha H, Barjila S, Ezzakkiouf F, Elmalki F. Prevalence of PMQR genes in E. coli and Klebsiella spp. isolated from North-West of Morocco. J Glob Antimicrob Resist. 2017;10:321–5.

52. Lachhab Z, Frkhi M, Maleb M, Kasouiti J, Doghmi N, Ben Lahlou Y, et al. Bacteremia in intensive care unit: clinical, bacteriological, and prognostic prospective study. Can J Infect Dis Med Microbiol. 2017;2017:1–9.

53. el Hamzaoui N, Bargiguia A, Larouz S, Maouloua M. Epidemiology of burn wound bacterial infections at a Melkins hospital, Morocco. N Microb N Med. 2020;38:100764.

54. Logman S, Sonaa N, Diene SM, Roinan J-M. Dissemination of carbapenemases (OXA-48, NDM and VIM) producing enterobacteriaceae isolated from the Mohamed VI University Hospital in Marrakesh, Morocco. Antibiotics. 2021;10:492.

55. El mekes A, Zahlane K, Ait said L, Tadlaoui Ouafi A, Barakate M. The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. J Infect Public Health. 2020;13:637–43.

56. el Kettani A, Maaloum F, Diawara I, Katfi K, Harrar N, Zerouali K, et al. Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochid University Hospital, Casablanca, Iran. J Microbiol. 2017;9:318–23.

57. Uwiringaye J, Frikh M, Lemouner A, Bissablie F, Belefquih B, Maleb A, et al. Acinetobacter infections prevalence and frequency of the antibiotic resistance: comparative study of intensive care units versus other hospital units. Pan Afr Med J. 2016;23.

58. Yacoubi L, Farih S, Benhamza N, Seddari A, Maleb A. Health vigilance of surgical wound infection caused by a multi drug resistant Streptococcus pneumoniae Serotype 19A after a total coloproctectomy with ileostomy. Pan Afr Med J. 2020;35.

59. Trappa C, Abo-Shهدa MN. Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review. BMC Infect Dis. 2020;20.

60. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González-U, et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17.

61. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Athery DE, et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016. Lancet Infect Dis. 2018;18:1229.

62. Lutgring JD. Carbapenem-resistant Enterobacteriaceae: an emerging bacterial threat: Semin Diagn Pathol. 2019;36:182.

63. Aurillo C, Sansone P, Barbarisi M, Potì V, Giaccari LG, Coppolino F, et al. Mechanisms of action of carbapenem resistance. Antibiotics. 2022;11:421.

64. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008;9:23–37.

65. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ. 2016. https://doi.org/10.1136/bmj.h6420.

66. Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014;5.

67. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca L, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev. 2018;31.

68. Grundmann H, Glaser C, Albigier A, Aanensen DM, Tomlinson CT, Andrasić AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17.

69. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of carbapenem-resistant enterococci infections: report from the China CRE Network. Antimicrob Agents Chemother. 2017;62.

70. Reed TAN, Kiang S, Miliya T, Townell N, Leitchford J, Eun S, et al. Antimicrobial resistance in Cambodia: a review. Int J Infect Dis. 2019;85:98–107.

71. Terre M, Taccani M, Pregnotolo M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules. 2021;26:2671.

72. Behzadi P, Garcia-Perdomo HA, Issakhanian L. Dissemination of carbapenem-resistant Acinetobacter baumannii strains carrying the blaGES, blaNDM and blaOXA23 in Morocco. Germs. 2020;30:102–7.

73. Reed TAN, Kiang S, Miliya T, Townell N, Leitchford J, Eun S, et al. Epidemiology of carbapenem-resistant enterococci infections: report from the China CRE Network. Antimicrob Agents Chemother. 2017;62.

74. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A systematic review and meta-analysis of the prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia. Antimicrob Agents Chemother. 2016.

75. Ayeram AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55:105833.

76. Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance fate for this antibiotic in pig production? Int J Antimicrob Agents. 2020;17:67622.

77. Agarwala RK, Prakash K, Pathak S, Parashar U, Prasad J, Oommen K, et al. Metallo-beta-lactamases: a review. Mol Biol Rep. 2020;47:6281–94.

78. Miyashita O, Ojika M, Akase D, Aida M, Igarashi Y, Ito Y, et al. d-Mannose binding, aggregation property, and antifungal activity of amide derivatives of pradinucin. Bioorg Med Chem. 2022;55:116590.

79. Sanhar M, Behzadi P, Ambrosi C, Zagaglia C, Palamara AT, Scribano D. 3-Fimt and anti-adhesive therapeutics: a disarming strategy against uropathogens. Antibiotics. 2020;9:397.

80. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A systematic review and meta-analysis of the prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia. Antimicrob Agents Chemother. 2016.

81. O’Neal L, Alvarez D, Mendizábal-Cabrera R, Ramay BM, Graham J. Community-acquired antimicrobial resistant Enterobacteriaceae in Central America: a one health systematic review. Int J Environ Res Public Health. 2020;17:7622.

82. Ayeram AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55:105833.

83. Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance in Pakistan: a systematic review of past decade. BMC Infect Dis. 2021;21.

84. Rhomua M, Seppä N, Letellier A. Resistance to colistin: what is the fate for this antibiotic in pig production? Int J Antimicrob Agents. 2016;48:119.

85. Frank D, Bouchef N, el Maadoudi M, Skali Senhaji N, Karraouan B, el Harsal A, et al. Prevalence, serotype distribution, and antimicrobial resistance of Salmonella isolated from food products in Morocco. J Infect Dev Countries. 2017;11:136–42.
131. Arhoune B, Oumokhtar B, Hmami F, Barguigua A, Timinouni M, el Fakir S, et al. Rectal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae among hospitalised neonates in a neonatal intensive care unit in Fez, Morocco. J Glob Antimicrob Resist. 2017;8:90–6.

132. Arhoune B, Oumokhtar B, Hmami F, Fakir S el, Moutaouakkil K, Chami F, et al. Intestinal carriage of antibiotic resistant Acinetobacter baumannii among newborns hospitalized in Moroccan neonatal intensive care unit. PLoS ONE. 2019;14.

133. Zahir H, Draiss G, Rada N, Abournahouat A, Ait sab I, Sbihi M, et al. Écologie microbienne et sensibilité aux antibiotiques des bactéries isolées d’infections urinaires chez l’enfant au Maroc. Rev Francoph Lab 2019;2019:65–70.

134. Torumkuney D, Hammami A, Mezghani Maalej S, ben Ayed N, Revathi G, Zerouali K, et al. Results from the survey of antibiotic resistance (SOAR) 2015–18 in Tunisia, Kenya and Morocco: data based on CLSI EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020;75.

135. Arhoune B, el Fakir S, Himri S, Moutaouakkil K, el Hassouni S, Ben-boubker M, et al. Intense intestinal carriage and subsequent acquisition of multidrug-resistant enterobacteria in neonatal intensive care unit in Morocco. PLoS ONE. 2021;16: e0251810.

136. Kettani Halabi M, Lahlou FA, Diawara I, el Adouzi Y, Marnaoui R, Bennes-saoud R, et al. Antibiotic resistance pattern of extended spectrum beta lactamase producing Escherichia coli isolated from patients with urinary tract infection in Morocco. Front Cell Infect Microbiol. 2021;11.

137. Rafik A, Abouddihaj B, Asmaa D, Kaotar N, Mohammed T. Antibiotic resistance profiling of Uropathogenic Enterobacteriaceae, Casablanca, Morocco. E3S Web Conf. 2021;319:01002.

138. Benaisa E, Elmrimar N, Belouad E, Mechal Y, Ghazouani M, Bsaibiss F, et al. Update on the resistance of Escherichia coli isolated from urine specimens in a Moroccan hospital: a review of a 7-year period. GERMS. 2021;11:189–98.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.